CDC25B exacerbates sepsis-associated intestinal injury by upregulating OLR1 and activating TNF‑α signaling
This study demonstrates that CDC25B exacerbates sepsis-associated intestinal injury by upregulating OLR1 and activating the TNF-α signaling pathway, thereby promoting barrier dysfunction and inflammation, which suggests CDC25B as a potential therapeutic target.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
When the body faces a severe infection, the immune system launches a massive defense to fight off the invading bacteria. Sometimes, this response becomes so intense and uncontrolled that it turns against the body itself, a condition known as sepsis. One of the most critical areas to suffer during this crisis is the intestine. The gut is lined with a delicate barrier made of tightly packed cells, acting like a security fence that keeps harmful toxins and bacteria inside the digestive tract while allowing nutrients to pass through. In sepsis, this fence begins to crumble. Gaps open up, allowing dangerous substances to leak into the bloodstream, which fuels the fire of inflammation and often leads to organ failure and death. While doctors know that this barrier breakdown is a major driver of the disease, the specific molecular switches that cause the fence to fall have remained largely a mystery.
A team of researchers at the First Affiliated Hospital of Bengbu Medical University in China has now identified one of these critical switches. They focused on a protein called CDC25B, a molecule previously known for its role in helping cells divide, but whose behavior during severe infection was unknown. By studying human tissue samples and growing human intestinal cells in the laboratory, the scientists discovered that CDC25B acts as a destructive force during sepsis. When the body is under attack, levels of this protein rise sharply in the gut. Instead of helping, this surge triggers a chain reaction that weakens the intestinal barrier and amplifies inflammation, making the condition much worse.
To understand how this happens, the researchers first looked at tissue samples from patients with sepsis and compared them to healthy controls. They found that the protein CDC25B was present in much higher amounts in the damaged intestinal tissue. To see exactly what this protein was doing, they turned to a laboratory model using Caco-2 cells, which are human intestinal cells grown in a dish. They exposed these cells to lipopolysaccharide, a substance found in the outer shell of certain bacteria that mimics a severe infection. As expected, the cells reacted by producing high levels of inflammatory signals and losing their structural integrity. However, when the researchers used a technique to reduce the amount of CDC25B in these cells, the damage was significantly less severe. The cells produced fewer inflammatory chemicals, suffered less from oxidative stress—a type of cellular damage caused by unstable molecules—and maintained a stronger barrier. Conversely, when they forced the cells to produce extra CDC25B, the damage became much worse, with the barrier breaking down more rapidly and inflammation spiking.
The study then dug deeper to find out how CDC25B causes this damage. The researchers used a method called RNA sequencing, which reads the genetic instructions inside the cells to see which genes are turned on or off. This analysis revealed that CDC25B acts as a master regulator for two specific targets. First, it increases the production of a receptor called OLR1, which sits on the surface of cells and helps trigger inflammation. Second, it activates a well-known signaling pathway involving a molecule called TNF-alpha, which is a primary driver of the inflammatory response. The data showed a clear line of cause and effect: when CDC25B levels were high, both OLR1 and TNF-alpha levels rose, leading to the activation of a cascade that breaks down the tight connections between intestinal cells. When CDC25B was reduced, these inflammatory signals dropped, and the connections between the cells remained more intact.
The researchers confirmed these findings by looking at the physical location of key proteins within the cells. They observed that CDC25B influences the movement of a protein called p65, which acts as a command center for inflammation. In cells with high levels of CDC25B, this command center moved into the nucleus, the control room of the cell, to turn on genes that promote inflammation and cell death. When CDC25B was removed, this movement was blocked, and the inflammatory response was dampened. The study suggests that CDC25B sits at the top of a harmful chain reaction, turning up the volume on OLR1 and TNF-alpha, which in turn destroys the intestinal barrier.
While the work was conducted in human cells and tissue samples rather than in living patients, the results point to a specific mechanism that could be targeted for treatment. The authors propose that finding a way to block CDC25B or its downstream effects might help preserve the intestinal barrier in sepsis patients, potentially stopping the cycle of inflammation that leads to organ failure. This research does not offer a cure, but it provides a clear map of a previously unknown pathway, suggesting that CDC25B and the molecules it controls could be valuable targets for future therapies aimed at protecting the gut during life-threatening infections.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.